络治法对糖尿病视网膜微血管损伤修复作用的研究
|
摘要
目的：针对糖尿病视网膜病变（DR）虚劳络阻的病机特点，以络病为切入点，评价络刺结合药物通络对DR微血管损伤的修复作用。方法：以大鼠作为实验研究对象，对其注射链佐脲菌素（STZ）进行DR造模，采用络刺加大黄蛰虫丸灌胃给药，治疗后观察以下指标：1.大鼠的体重、血糖、糖化血红蛋白及血浆纤维蛋白原，并观察白内障的发生率。2.眼底荧光血管造影（FFA）观察DR大鼠眼底血管管径、荧光素渗漏形态及面积的变化。3.视网膜组织石蜡切片结合HE染色，光镜下观察视网膜各层组织结构的变化。4.视网膜组织石蜡切片联合免疫组织化学法，观察视网膜中核因子-κb（nf-κb）的表达。5.视网膜消化铺片联合PAS染色，观察对视网膜微血管形态学上的改变。6.视网膜消化铺片结合免疫荧光染色技术，观察视网膜血管壁中血管细胞粘附分子-1（VCAM-1）的表达。结果：1.络治能明显改善糖尿病大鼠三多一少等症状，减轻血糖的增高对大鼠体重的影响，降低血液中纤维蛋白原含量。2.FFA显示，络治能减少DR大鼠眼底新生血管的生成，减轻血管渗漏。3.视网膜组织切片形态学观察结果显示，络治能明显减轻视网膜组织水肿程度，减轻神经细胞损伤，抑制新生血管生成。4.免疫组织化学染色显示，络治可下调视网膜中nf-κb的表达。5.视网膜消化铺片联合PAS染色及免疫荧光染色显示络治能改善微血管网形态，并下调血管壁中炎性因子VCAM-1的表达。结论：络治法能够有效减轻高血糖引起的视网膜微血管损伤，改善糖尿病视网膜微血管的结构与机能，改善微血管管壁的通透性，抑制或消除诱发的出血、渗出，实现对视网膜保护作用。其作用机理可能是通过调节血浆中纤维蛋白原的含量，降低了血液粘稠度，增加局部视网膜血流量及氧供，抑制视网膜中nf-κb的活化及下游VCAM-1等炎性因子的表达等方面得以实现。上述研究成果在丰富中医络脉理论的同时，为DR的防治提供了新的思路与方法。
Objective: For diabetic retinopathy (DR) characteristics of consumptive diseasepathogenesis of collaterals, by collateral disease as the breakthrough point to evaluate thethe role in repairment of diabetic retinal microvascular injury treated with the collateralneedling and drug。 Methods: Using rats as experimental subjects， by injection ofstreptozocin (STZ) into DR model，after treatment with Dahuang Zhechong pillsintragastric administration and collateral puncture，in observation of the followingindicators:1.Rat body weight、blood glucose、glycosylated haemoglobin、plasmafibrinogen and the incidence of cataracts.2. By fundus fluorescein angiography (FFA), toobserve the changes of retinal vessel diameter of DR rats, fluorescein leakage area andshape.3.By paraffin section of retinal tissue combined with HE staining method,to observethe change of every layer of retina tissue structure under light microscope.4.By paraffinsection of retinal tissue combined with immunohistochemical method,to observe theexpression of retinal nuclear factor-κb (nf-κb)。5. Through the retinal digest preparationscombined with PAS staining, to observe retinal microvascular changes inmorphology.6.Through the retinal digest preparations combined with immunofluorescencetechnique, to observe the expression of vascular cell adhesion molecule-1(VCAM-1) inretinal vascular wall.Results:1.Collaterals therapy can significantly change the symptomsof“three more and one less”in DR rats, reduce the effect of high glucose on rat bodyweight,and reduce blood fibrinogen content.2.FFA showed that collaterals therapy canreduce the generation of DR rat retinal neovascularization，and can reduce vascularleakage.3. Morphological observation of retinal tissue biopsies showed that collateralstherapy can significantly reduce the degree of retinal edema, reducing neuronal damage,inhibit tumor angiogenesis.4.Immunohistochemistry showed collaterals treatmentdecreased expression of nf-κB in retina.5.Retinal digest preparations combined with PAS and immunofluorescence showed collaterals therapy can improve the microvascularmorphology, and reduce the expression of inflammatory factor VCAM-1in the vascularwall.Conclusion: Collateral treatment can effectively alleviate the hyperglycemia inducedby retinal microvascular injury, improve diabetic retinal structure and function of bloodvessels, change the microvessel wall permeability, inhibit or eliminate induced hemorrhageand exudation, thus realizing the retinal protection. Its mechanism may be through theregulation of fibrinogen in plasma content, reducing the blood viscosity, increase the flowand oxygen partial retinal blood supply, inhibit the expression of retinal nf-κB activationand downstream of the VCAM-1and other inflammatory factors. The above researchresults in the rich of traditional Chinese collaterals theory,and at the same time providesnew ideas and methods for the prevention and treatment of DR.
Objective: For diabetic retinopathy (DR) characteristics of consumptive diseasepathogenesis of collaterals, by collateral disease as the breakthrough point to evaluate thethe role in repairment of diabetic retinal microvascular injury treated with the collateralneedling and drug。 Methods: Using rats as experimental subjects， by injection ofstreptozocin (STZ) into DR model，after treatment with Dahuang Zhechong pillsintragastric administration and collateral puncture，in observation of the followingindicators:1.Rat body weight、blood glucose、glycosylated haemoglobin、plasmafibrinogen and the incidence of cataracts.2. By fundus fluorescein angiography (FFA), toobserve the changes of retinal vessel diameter of DR rats, fluorescein leakage area andshape.3.By paraffin section of retinal tissue combined with HE staining method,to observethe change of every layer of retina tissue structure under light microscope.4.By paraffinsection of retinal tissue combined with immunohistochemical method,to observe theexpression of retinal nuclear factor-κb (nf-κb)。5. Through the retinal digest preparationscombined with PAS staining, to observe retinal microvascular changes inmorphology.6.Through the retinal digest preparations combined with immunofluorescencetechnique, to observe the expression of vascular cell adhesion molecule-1(VCAM-1) inretinal vascular wall.Results:1.Collaterals therapy can significantly change the symptomsof“three more and one less”in DR rats, reduce the effect of high glucose on rat bodyweight,and reduce blood fibrinogen content.2.FFA showed that collaterals therapy canreduce the generation of DR rat retinal neovascularization，and can reduce vascularleakage.3. Morphological observation of retinal tissue biopsies showed that collateralstherapy can significantly reduce the degree of retinal edema, reducing neuronal damage,inhibit tumor angiogenesis.4.Immunohistochemistry showed collaterals treatmentdecreased expression of nf-κB in retina.5.Retinal digest preparations combined with PAS and immunofluorescence showed collaterals therapy can improve the microvascularmorphology, and reduce the expression of inflammatory factor VCAM-1in the vascularwall.Conclusion: Collateral treatment can effectively alleviate the hyperglycemia inducedby retinal microvascular injury, improve diabetic retinal structure and function of bloodvessels, change the microvessel wall permeability, inhibit or eliminate induced hemorrhageand exudation, thus realizing the retinal protection. Its mechanism may be through theregulation of fibrinogen in plasma content, reducing the blood viscosity, increase the flowand oxygen partial retinal blood supply, inhibit the expression of retinal nf-κB activationand downstream of the VCAM-1and other inflammatory factors. The above researchresults in the rich of traditional Chinese collaterals theory,and at the same time providesnew ideas and methods for the prevention and treatment of DR.
引文
[1]徐叔云,卞如濂,陈修等.药理实验方法学.北京：人民卫生出版社,1982,第三版:附录.
[2]段俊国，彭清华，王育良等.中西医结合眼科学.北京：中国中医药出版社，2005，第一版：261.
[3]刘求红．余杨桂教授治疗糖尿病性视网膜病变的思路与经验[J]．黑龙江中医药，2004，18(2):26－27．
[4]梁光宇．冯明清教授治疗糖尿病学术思想简介[J]．河南中医，2000，20(1):15．
[5]吕仁和，赵进喜，王世东．糖尿病及其并发症的临床研究[J]．新中医，2001，33(3):3－5．
[6]欧阳永斌．论痰阻目络是非胰岛素依赖型糖尿病视网膜病变的基本病机之一[J]．浙江中医杂志，2002，37(2):47－48．
[7]李华，黄平．糖尿病视网膜病变从痰瘀论治[J]．浙江中医学院学报，2003，27(4):23－24．
[8]倪青．著名中医学家林兰教授学术经验之十一病位侧重肝脾肾治宜祛瘀重养[J]．辽宁中医杂志，2001，28(5):259－260．
[9]文小敏，丁辉．浅谈糖尿病视网膜病变中瘀血病理机制初探[J]．陕西中医，2003，24(10):959－960．
[10]王军，朱虹，从瘀热阻络论治糖尿病视网膜病变[J]．中医杂志，2008，49(7):666．
[11]李志英，余杨桂，张淳，等．糖尿病中医证型与糖尿病视网膜病变分期关系的探讨[J]．中国中医眼科杂志，2000，10(1):29－32．
[12]李红，夏建生．糖尿病视网膜病变辨证及分型的临床研究[J]．河南中医，2000，20(9):33．
[13]易细香，余杨桂，张淳，等．糖尿病视网膜病变的证候统计与病机研究[J]．辽宁中医杂志，2005，32(8):773－775．
[14]姜小帆，邵明义，蔡东海，等．糖尿病视网膜病变辨证分型及证候要素分布的文献研究[J]．时珍国医国药，2009，20(12):3171－3173．
[15]金宝良.糖尿病继发视网膜病变的分型辨治及体会[J].河北中医,1997,19(2):22.
[16]张兰,闫景亮.糖尿病性眼底病出血探析[J].辽宁中医杂志,1997,24(10):455.
[17]涂良钰.中西医结合治疗眼科常见病[M].广州:广东人民出版社,1998.331.
[18]何学军.辨证论治糖尿病合并视网膜病变12例[J].光明中医,2010,25(2)：294－295.
[19]王伟.中药治疗糖尿病视网膜病变33例临床分析[J].中医药学报,2010,38(1)：113－114.
[20]姚敏，郑军.中医对糖尿病视网膜病变认识的现状[J].中医药学报，2003.31(3):60
[21]谭达全，邓冰湘论络病[J].中医药学刊，2005；23（7）：1237-1240.
[22]雷燕，王永炎，黄启福。论瘀毒阻络是络病形成的病理基础[J].北京中医药大学学报，1999；22（2）：8-10.
[23]郭承伟，张宏国，马栋.从络论治糖尿病视网膜病变的理论与应用探讨[J].中国中医眼科杂志,2011;21(5):255-256
[24]傅仁宁.中医五官名著集成之审视瑶函[M].北京：华夏出版社，1998；234
[25]亢泽峰，庄曾渊.瞳神络病病机及其证治探析[J].北京中医药大学学报，2003；26（4）：77-79
[26]杨俊伟,黎磊石大黄延缓慢性肾衰进展的实验研究〔J〕中华肾脏病杂志,1993;9(2):65-8
[27]杨耀芳,杨翊文,王赛前,等土鳖虫口服液镇痛、活血化瘀与红细胞免疫研究〔J〕中成药,2003;25(6):496-8
[28]王玮,吴莹瑶,卢岩,等野黄芩甙抗炎作用的实验研究〔J〕中国医科大学学报,2003;32(6):503-4
[29]周乐，赵文静，常惟智.水蛭的药理作用及临床应用研究进展[J].中医药信息，2012；29（1）：132
[30]成家茂，潘志恒，陈海燕．大黄蜇虫丸的现代共用及作用机制[J]．云南中医中药杂志，2009，30（2）：67-68．
[31]李文，王利，吴诗品．大黄蜇虫丸治疗慢性肝炎肝纤维化的临床疗效观察[J]．中国药房，2008，19（21）：1658-1660．
[32]江玉娟，司秋菊，张艳慧，等．大黄蜇虫丸对动脉硬化大鼠核因子-kB蛋白表达的影响[J]．中国老年学杂志，2011，1（31）：113-115．
[33]王东生，陈方平，贺石林，等．大黄虫丸血浆药理学与血清药理学作用的比较研究[J]．血栓与止血学，2005，11（1）：5-8．
[34]张雪花，周德生．大黄虫丸临床应用进展[J]．河南中医，2007，（11）：87-88．
[35]陈俊发．大黄蜇虫丸治疗颈动脉粥样硬化斑块50例[J]．山东中医杂志，2001，21（6）：331-332．
[36]陈小凯，吴虹，李旅萍，等.刺络放血法治疗颈椎病对ICAM－1影响的临床观察[J].亚太传统医药，2008，4(3):60～63.
[37]徐斌.刺络放血疗法的血管生物学基础[J].中国临床康复，2004，4(8):5126～5127.
[38]李洁新.刺络放血疗法在中风治疗中的应用[J].首都医药，2006，(12):47～48
[39]李佩芳，曹奕，王二争.刺络放血对Ⅱ型糖尿病周围神经病变和血液流变学的影响[J].针灸临床杂志，2004，20(12):38～40.
[40]韩宝杰，励志英.刺络疗法对中风病患者血液流变学影响的临床观察[J].天津中医，2001，18(1):27～28.
[41]张建斌，姜亚军，芦慧霞，等.刺络放血疗法对脑梗死恢复期患者凝血系统的影响[J].中国针灸，2003，23(1):44～47.
[42]崔峻，魏华娥，刘星.综合刺络疗法治疗急性期肩周炎临床及血液流变学的影响[J].江西中医药，200536(274):55～56.
[43]周智梁.手十二井穴刺络放血及电针对家兔脑血流图影响的中枢神经递质机理探讨[J].针刺研究，1998，4(4):254～257.
[44]王盛春,尹红博针刺太冲对缺血性中风恢复期患者颅内动脉的影响及其与时效关系的研究，山东中医药大学学报，2008，2（6）：466
[45]张慧敏，费宇彤，时宇静等，针刺“百会”“太阳”改善局灶性脑缺血脑微血管内皮细胞功能的动态观察，针刺研究2006，31（2）：67
[46] DagherZ, Park YS, AsnaghiV, et al. Studies of rat and human retinaspredicta role for the polyolpathway in human diabetic retinopathy.Diabetes2004;53(9):2404-2411
[47] AsnaghiV, Gerhardinger C, Hoehn T, et al. A role for the polyol pathwayin the early neuroretinal apoptosis and glial changes induced by diabetesin the rat Diabetes2003;52(2):506-511
[48] CheungAK, FungMK, LoAC, et al. Aldose reductase deficiency preventsdiabetes-induced blood-retinal barrier breakdown, apoptosis,and glialreactivation in the retina of db/db mice. Diabetes2005;54(11):3119-3125
[49] Lu TT, Yan LG, Madri JA. Integrin engagement mediates tyrosinedephosphorylation on platelet-endothelial cell adhesionmolecule1.ProcN atlAcad SciUSA1996;93(21):11808-11813
[50] Bursell SE, ClermontAC, Kinsley BT, et al. Retinal blood flow changesin patients with insulin dependent diabetes mellitusand nodiabet-icretinopathy. InvestOphthalmolVis Sci1996;37(5):886-897
[51] AielloLP, AveryRL, Arrigg PG, et al. Vascular endothelial growth factorin ocular fluid of patients with diabetic retinopathy and other retinaldisorders. N Engl JMed1994;331(22):1480-1487
[52]MacGregorLC, MatschinskyFM. Altered retinal metabolism in diabetes. II.Measurement of sodium potasium ATPase and total sodium and potassium inindividual retinal layers. J Biol Chem1986;261(9):4052-4058
[53] Wautier JL, Guillausseau PJ. Advanced glycation end products, theirreceptors and diabetic angiopathy. DiabeteMetab2001;27(5):535-542
[54] StittAW, LiYM, GardinerTA, etal. Advanced glycation end products (AGEs)co-localize with AGE receptors in the retinalvasculature of diabetic andofAGE-infused rats. Am JPathol1997;150(2):523-531
[55] Lecleire-ColletA, TessierLH, Massin P, et al. Advanced glycation endproducts can induce glial reaction and neuronaldegeneration in retinalexplants. Br JOphthalmol2005;89(12):1631-1633
[56] MooreTC, Moore JE, KajiY, et al. The role of advanced glycation endproducts in retinal microvascular leukostasis. Invest OphthalmolVisSci2003;44(10):4457-4464
[57] LiWL, JiangDY, GuoLH, etal. Pueravin inhibits the prociferation of humanretinal pigment epithelial cell sand the expression of hypoxia-induciblefactor-1αin humanPRE cells induced by advanced glycation end products.Int J Ophthalmol(GuojiYanke Zazhi)2006;6(3):580-583
[58] TreinsC, Giorgetti-PeraldiS, Murdaca J, etal. Regulation of vascularendothelial growth factor expression by advanced glycation end products.JBiolChem2001;276(47):43836-43841
[59] AntonettiDA, BarberAJ, HollingerLA, et al. Vascular endothelial growthfactor induces rapid phosphorylation of tight junction proteins occludinand zonula occluden1. A potential mechanism for vascular permeabilityin diabetic retinopathy and tumors. J BiolChem1999;274(33):23463-23467
[60] CutlerRG. Oxidative stress profiling: part I. Its potential importancein the optmization of human health. Ann N Y Acad Sci2005;1055:93-135
[61] HaskinsK, BradleyB, PowersK, etal. Oxidative stress in type1diabetes.AnnN Y Acad Sci2003;1005:43-54
[62] TakamuraY, TomomatsuT, KuboE, etal. Role of the polyol pathway in highglucose-induced apoptosis of retinal pericytes and proliferation ofendothelial cells. Invest Ophthalmol Vis Sci2008;49(7):3216-3223
[63] KowluruRA. Effect of advanced glycation end productson acceleratedapoptosis of retinal capillary cells under in vitro conditions. LifeSci2005;76(9):1051-1060.[64] DuXL, EdelsteinD, RossettiL, et al. Hyper glycemia inducedmitochondrial superoxide over production activates the hexosaminepathway and induces plasminogen activator inhibitor-1expression byincreasing Sp1glycosylation. ProcNatlAcad SciUSA2000;97(22):12222-12226
[65] ZhangXL, Qiu SD, ChenYJ, etal. An overview of the pathogenesis ofdiabetic retinopathy. Int J Ophthalmol(Guoji Yanke Zazhi)2005;5(6):1239-1241
[66] LiH, Hu XL. Role of vascular endothelial growth factor in the progressof diabetic retinopathy. Int J Ophthalmol(Guoji YankeZazhi)2008;8(5):990-993
[67] PoulakiV, JoussenAM, MitsiadesN, et al. Insulin-like growth factor-Iplays a pathogenetic role in diabetic retinopathy. Am JPathol2004;165(2):457-469
[68] DawsonDW, VolpertOV, GillisP, etal. Pigment epithelium-derived factor:a potent inhibitor of angiogenesis. Science1999;285(5425):245-248
[69] HaWJ, YanH. The role of inflammationin diabetic retinopathy.IntJOphthalmol(GuojiYanke Zazhi)2005;5(4):745-749
[70] ZhengL, SzabóC, Kern TS. Poly(ADP-ribose) polymerase is involved in thedevelopment of diabetic retinopathy via regulation of nuclearfactor-kappaB. Diabetes2004;53(11):2960-2967
[71] YemeniKK，BaiW，KhanBV，etal.Hyperglyce induced action of nucleartranscription factor kappaB in vascular smoth muscle cells. Diabetes.1999,48:855-864
[72]赵延春.核因子-kB与糖尿病血管病变[J].国外医学内分泌学分册，2004，24:35-36
[2]段俊国，彭清华，王育良等.中西医结合眼科学.北京：中国中医药出版社，2005，第一版：261.
[3]刘求红．余杨桂教授治疗糖尿病性视网膜病变的思路与经验[J]．黑龙江中医药，2004，18(2):26－27．
[4]梁光宇．冯明清教授治疗糖尿病学术思想简介[J]．河南中医，2000，20(1):15．
[5]吕仁和，赵进喜，王世东．糖尿病及其并发症的临床研究[J]．新中医，2001，33(3):3－5．
[6]欧阳永斌．论痰阻目络是非胰岛素依赖型糖尿病视网膜病变的基本病机之一[J]．浙江中医杂志，2002，37(2):47－48．
[7]李华，黄平．糖尿病视网膜病变从痰瘀论治[J]．浙江中医学院学报，2003，27(4):23－24．
[8]倪青．著名中医学家林兰教授学术经验之十一病位侧重肝脾肾治宜祛瘀重养[J]．辽宁中医杂志，2001，28(5):259－260．
[9]文小敏，丁辉．浅谈糖尿病视网膜病变中瘀血病理机制初探[J]．陕西中医，2003，24(10):959－960．
[10]王军，朱虹，从瘀热阻络论治糖尿病视网膜病变[J]．中医杂志，2008，49(7):666．
[11]李志英，余杨桂，张淳，等．糖尿病中医证型与糖尿病视网膜病变分期关系的探讨[J]．中国中医眼科杂志，2000，10(1):29－32．
[12]李红，夏建生．糖尿病视网膜病变辨证及分型的临床研究[J]．河南中医，2000，20(9):33．
[13]易细香，余杨桂，张淳，等．糖尿病视网膜病变的证候统计与病机研究[J]．辽宁中医杂志，2005，32(8):773－775．
[14]姜小帆，邵明义，蔡东海，等．糖尿病视网膜病变辨证分型及证候要素分布的文献研究[J]．时珍国医国药，2009，20(12):3171－3173．
[15]金宝良.糖尿病继发视网膜病变的分型辨治及体会[J].河北中医,1997,19(2):22.
[16]张兰,闫景亮.糖尿病性眼底病出血探析[J].辽宁中医杂志,1997,24(10):455.
[17]涂良钰.中西医结合治疗眼科常见病[M].广州:广东人民出版社,1998.331.
[18]何学军.辨证论治糖尿病合并视网膜病变12例[J].光明中医,2010,25(2)：294－295.
[19]王伟.中药治疗糖尿病视网膜病变33例临床分析[J].中医药学报,2010,38(1)：113－114.
[20]姚敏，郑军.中医对糖尿病视网膜病变认识的现状[J].中医药学报，2003.31(3):60
[21]谭达全，邓冰湘论络病[J].中医药学刊，2005；23（7）：1237-1240.
[22]雷燕，王永炎，黄启福。论瘀毒阻络是络病形成的病理基础[J].北京中医药大学学报，1999；22（2）：8-10.
[23]郭承伟，张宏国，马栋.从络论治糖尿病视网膜病变的理论与应用探讨[J].中国中医眼科杂志,2011;21(5):255-256
[24]傅仁宁.中医五官名著集成之审视瑶函[M].北京：华夏出版社，1998；234
[25]亢泽峰，庄曾渊.瞳神络病病机及其证治探析[J].北京中医药大学学报，2003；26（4）：77-79
[26]杨俊伟,黎磊石大黄延缓慢性肾衰进展的实验研究〔J〕中华肾脏病杂志,1993;9(2):65-8
[27]杨耀芳,杨翊文,王赛前,等土鳖虫口服液镇痛、活血化瘀与红细胞免疫研究〔J〕中成药,2003;25(6):496-8
[28]王玮,吴莹瑶,卢岩,等野黄芩甙抗炎作用的实验研究〔J〕中国医科大学学报,2003;32(6):503-4
[29]周乐，赵文静，常惟智.水蛭的药理作用及临床应用研究进展[J].中医药信息，2012；29（1）：132
[30]成家茂，潘志恒，陈海燕．大黄蜇虫丸的现代共用及作用机制[J]．云南中医中药杂志，2009，30（2）：67-68．
[31]李文，王利，吴诗品．大黄蜇虫丸治疗慢性肝炎肝纤维化的临床疗效观察[J]．中国药房，2008，19（21）：1658-1660．
[32]江玉娟，司秋菊，张艳慧，等．大黄蜇虫丸对动脉硬化大鼠核因子-kB蛋白表达的影响[J]．中国老年学杂志，2011，1（31）：113-115．
[33]王东生，陈方平，贺石林，等．大黄虫丸血浆药理学与血清药理学作用的比较研究[J]．血栓与止血学，2005，11（1）：5-8．
[34]张雪花，周德生．大黄虫丸临床应用进展[J]．河南中医，2007，（11）：87-88．
[35]陈俊发．大黄蜇虫丸治疗颈动脉粥样硬化斑块50例[J]．山东中医杂志，2001，21（6）：331-332．
[36]陈小凯，吴虹，李旅萍，等.刺络放血法治疗颈椎病对ICAM－1影响的临床观察[J].亚太传统医药，2008，4(3):60～63.
[37]徐斌.刺络放血疗法的血管生物学基础[J].中国临床康复，2004，4(8):5126～5127.
[38]李洁新.刺络放血疗法在中风治疗中的应用[J].首都医药，2006，(12):47～48
[39]李佩芳，曹奕，王二争.刺络放血对Ⅱ型糖尿病周围神经病变和血液流变学的影响[J].针灸临床杂志，2004，20(12):38～40.
[40]韩宝杰，励志英.刺络疗法对中风病患者血液流变学影响的临床观察[J].天津中医，2001，18(1):27～28.
[41]张建斌，姜亚军，芦慧霞，等.刺络放血疗法对脑梗死恢复期患者凝血系统的影响[J].中国针灸，2003，23(1):44～47.
[42]崔峻，魏华娥，刘星.综合刺络疗法治疗急性期肩周炎临床及血液流变学的影响[J].江西中医药，200536(274):55～56.
[43]周智梁.手十二井穴刺络放血及电针对家兔脑血流图影响的中枢神经递质机理探讨[J].针刺研究，1998，4(4):254～257.
[44]王盛春,尹红博针刺太冲对缺血性中风恢复期患者颅内动脉的影响及其与时效关系的研究，山东中医药大学学报，2008，2（6）：466
[45]张慧敏，费宇彤，时宇静等，针刺“百会”“太阳”改善局灶性脑缺血脑微血管内皮细胞功能的动态观察，针刺研究2006，31（2）：67
[46] DagherZ, Park YS, AsnaghiV, et al. Studies of rat and human retinaspredicta role for the polyolpathway in human diabetic retinopathy.Diabetes2004;53(9):2404-2411
[47] AsnaghiV, Gerhardinger C, Hoehn T, et al. A role for the polyol pathwayin the early neuroretinal apoptosis and glial changes induced by diabetesin the rat Diabetes2003;52(2):506-511
[48] CheungAK, FungMK, LoAC, et al. Aldose reductase deficiency preventsdiabetes-induced blood-retinal barrier breakdown, apoptosis,and glialreactivation in the retina of db/db mice. Diabetes2005;54(11):3119-3125
[49] Lu TT, Yan LG, Madri JA. Integrin engagement mediates tyrosinedephosphorylation on platelet-endothelial cell adhesionmolecule1.ProcN atlAcad SciUSA1996;93(21):11808-11813
[50] Bursell SE, ClermontAC, Kinsley BT, et al. Retinal blood flow changesin patients with insulin dependent diabetes mellitusand nodiabet-icretinopathy. InvestOphthalmolVis Sci1996;37(5):886-897
[51] AielloLP, AveryRL, Arrigg PG, et al. Vascular endothelial growth factorin ocular fluid of patients with diabetic retinopathy and other retinaldisorders. N Engl JMed1994;331(22):1480-1487
[52]MacGregorLC, MatschinskyFM. Altered retinal metabolism in diabetes. II.Measurement of sodium potasium ATPase and total sodium and potassium inindividual retinal layers. J Biol Chem1986;261(9):4052-4058
[53] Wautier JL, Guillausseau PJ. Advanced glycation end products, theirreceptors and diabetic angiopathy. DiabeteMetab2001;27(5):535-542
[54] StittAW, LiYM, GardinerTA, etal. Advanced glycation end products (AGEs)co-localize with AGE receptors in the retinalvasculature of diabetic andofAGE-infused rats. Am JPathol1997;150(2):523-531
[55] Lecleire-ColletA, TessierLH, Massin P, et al. Advanced glycation endproducts can induce glial reaction and neuronaldegeneration in retinalexplants. Br JOphthalmol2005;89(12):1631-1633
[56] MooreTC, Moore JE, KajiY, et al. The role of advanced glycation endproducts in retinal microvascular leukostasis. Invest OphthalmolVisSci2003;44(10):4457-4464
[57] LiWL, JiangDY, GuoLH, etal. Pueravin inhibits the prociferation of humanretinal pigment epithelial cell sand the expression of hypoxia-induciblefactor-1αin humanPRE cells induced by advanced glycation end products.Int J Ophthalmol(GuojiYanke Zazhi)2006;6(3):580-583
[58] TreinsC, Giorgetti-PeraldiS, Murdaca J, etal. Regulation of vascularendothelial growth factor expression by advanced glycation end products.JBiolChem2001;276(47):43836-43841
[59] AntonettiDA, BarberAJ, HollingerLA, et al. Vascular endothelial growthfactor induces rapid phosphorylation of tight junction proteins occludinand zonula occluden1. A potential mechanism for vascular permeabilityin diabetic retinopathy and tumors. J BiolChem1999;274(33):23463-23467
[60] CutlerRG. Oxidative stress profiling: part I. Its potential importancein the optmization of human health. Ann N Y Acad Sci2005;1055:93-135
[61] HaskinsK, BradleyB, PowersK, etal. Oxidative stress in type1diabetes.AnnN Y Acad Sci2003;1005:43-54
[62] TakamuraY, TomomatsuT, KuboE, etal. Role of the polyol pathway in highglucose-induced apoptosis of retinal pericytes and proliferation ofendothelial cells. Invest Ophthalmol Vis Sci2008;49(7):3216-3223
[63] KowluruRA. Effect of advanced glycation end productson acceleratedapoptosis of retinal capillary cells under in vitro conditions. LifeSci2005;76(9):1051-1060.[64] DuXL, EdelsteinD, RossettiL, et al. Hyper glycemia inducedmitochondrial superoxide over production activates the hexosaminepathway and induces plasminogen activator inhibitor-1expression byincreasing Sp1glycosylation. ProcNatlAcad SciUSA2000;97(22):12222-12226
[65] ZhangXL, Qiu SD, ChenYJ, etal. An overview of the pathogenesis ofdiabetic retinopathy. Int J Ophthalmol(Guoji Yanke Zazhi)2005;5(6):1239-1241
[66] LiH, Hu XL. Role of vascular endothelial growth factor in the progressof diabetic retinopathy. Int J Ophthalmol(Guoji YankeZazhi)2008;8(5):990-993
[67] PoulakiV, JoussenAM, MitsiadesN, et al. Insulin-like growth factor-Iplays a pathogenetic role in diabetic retinopathy. Am JPathol2004;165(2):457-469
[68] DawsonDW, VolpertOV, GillisP, etal. Pigment epithelium-derived factor:a potent inhibitor of angiogenesis. Science1999;285(5425):245-248
[69] HaWJ, YanH. The role of inflammationin diabetic retinopathy.IntJOphthalmol(GuojiYanke Zazhi)2005;5(4):745-749
[70] ZhengL, SzabóC, Kern TS. Poly(ADP-ribose) polymerase is involved in thedevelopment of diabetic retinopathy via regulation of nuclearfactor-kappaB. Diabetes2004;53(11):2960-2967
[71] YemeniKK，BaiW，KhanBV，etal.Hyperglyce induced action of nucleartranscription factor kappaB in vascular smoth muscle cells. Diabetes.1999,48:855-864
[72]赵延春.核因子-kB与糖尿病血管病变[J].国外医学内分泌学分册，2004，24:35-36